NEW YORK — A new, higher-dose nasal spray for reversing opioid overdoses did not save more lives than the previous standard dose, but it did cause more vomiting and other side effects, researchers ...
A study comparing a new, higher-dose nasal spray for opioid overdoses to the standard dose found no increase in survival rates but more side effects. The 8-milligram naloxone spray, approved two years ...
U.S. regulators on Friday approved the first high-dose nasal spray for reversing opioid overdoses. The Food and Drug Administration approved Hikma Pharmaceuticals’ Kloxxado, a spray containing 8 ...
NSYS Therapeutics' SUBSYS™, which uses an Aptar Pharma Sublingual Unit-Dose Spray (UDS) device, has been launched in the USA for breakthrough cancer pain in patients with cancer who are 18 years of ...
FILE - This image provided by Hikma Pharmaceuticals shows the company's nasal spray drug Kloxxado, containing 8 milligrams of naloxone. A study published Thursday, Feb. 8, 2024 finds that a new, ...
U.S. regulators on Friday approved the first high-dose nasal spray for reversing opioid overdoses. The Food and Drug Administration approved Hikma Pharmaceuticals’ Kloxxado, a spray containing 8 ...
NEW YORKNEW YORK — A new, higher-dose nasal spray for reversing opioid overdoses did not save more lives than the previous standard dose, but it did cause more vomiting and other side effects, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback